The original SaaS business hit a big milestone recently, we recap how the company turned CRM into a business worth over $100 billion. Then we turn our attention to a SaaS stock that's still in its early innings, Shopify.
To wrap things up, we get some tips on how to talk about money with kids from a visiting team of junior analysts.
An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.
T-Mobile and Sprint have faced opposition from federal regulators over their planned $26.5 billion merger. Speculation that the deal may not be approved has led Sprint to send a statement to the Department of Justice saying that if the deal gets denied, it may not be able to survive. Fool Contributor Daniel Kline joins Shannon Jones to break that down and to take some time to sort out the streaming video industry.
On this episode of Industry Focus: Financials, Fool.com contributor Matt Frankel, CFP sits down with Gunther Bright, Executive Vice President, Merchant Services U.S. for American Express to discuss how Amex has evolved in recent years. After, Frankel and host Jason Moser discuss a trio of earnings from Bank of America (NYSE: BAC), Morgan Stanley (NYSE: MS), and Travelers (NYSE: TRV) and answer a listener question about investing in wealth management firms. And, as always, we close out the show with two stocks we’re keeping our eye on now.
Last Friday, Chevron announced a $33 billion acquisition of Anadarko Petroleum, one of the biggest energy mergers in years. Motley Fool Contributor Matt Dilallo and Industry Focus host Nick Sciple break down the deal, take a look at Kinder Morgan’s most recent earnings report, and preview upcoming earnings from some of their favorite oil companies.
Marijuana stocks OrganiGram and Aphria reported quarterly earnings this week - here's what you should know. Also, Abbott locks horns with DexCom in diabetes and what's next for Bristol-Myers' now that its Celgene acquisition is official.
We're tapping deep into childhood nostalgia on this show -- kids birthday party staple Chuck E. Cheese is planning to go public in 2019 and the details on Disney+ are finally available. One of these developments should have investors happy, the other one... not so much.
In this episode, we look at the bank earnings (so far) and learn about person-to-person payment platform Zelle. In the latest edition of our Between Two Fools interview series, Fool.com contributor Matt Frankel, CFP sits down with Lou Anne Alexander, Group President of Payments for Early Warning, the company behind person-to-person payment platform Zelle. Later, Frankel and Industry Focus: Financials host Jason Moser discuss earnings from JPMorgan Chase (NYSE: JPM), and both tell listeners about the stocks on their radar this week.
Soon-to-be-public Zoom is a Unicorn among Unicorns -- the company grew its top line over 100% last year and it managed to post a profit. We run through the company prospectus and see whether it is worth investing in ahead up its public debut:
4 years ago, Dow and DuPont merged, creating one of the world’s largest industrial conglomerates. From the start, the plan was to break this newly formed company into 3 separate businesses, each more streamlined and nimble than the combined entity. In early April, the first stage of the breakup took place when New Dow began trading. Motley Fool Contributor Lou Whiteman and Industry Focus host Nick Sciple break down each of the newly formed companies and discuss how investors should be viewing them as they come to market.
Here's why a $1 billion deal with Regeneron failed to spark a rally in Alnylam shares. Also, will genetic discovery be our generation's biggest trend? If so, Illumina, bluebird bio, and Invitae could be top stocks to watch.
Get more great information on becoming a better investor -- free and straight to your inbox!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Statement and Terms & Conditions.